CA3114669A1 - Humanised anti-n-truncated amyloid beta monoclonal antibody - Google Patents

Humanised anti-n-truncated amyloid beta monoclonal antibody Download PDF

Info

Publication number
CA3114669A1
CA3114669A1 CA3114669A CA3114669A CA3114669A1 CA 3114669 A1 CA3114669 A1 CA 3114669A1 CA 3114669 A CA3114669 A CA 3114669A CA 3114669 A CA3114669 A CA 3114669A CA 3114669 A1 CA3114669 A1 CA 3114669A1
Authority
CA
Canada
Prior art keywords
antibody
nt4x
seq
antibodies
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3114669A
Other languages
English (en)
French (fr)
Inventor
Thomas Bayer
Preeti BAKRANIA
Sarah Davies
Alex Brown
Chido MPAMHANGA
David Matthews
Mark Carr
Gareth HALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsmedizin Goettingen Georg August Universitaet
LifeArc
Original Assignee
Universitaetsmedizin Goettingen Georg August Universitaet
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsmedizin Goettingen Georg August Universitaet, LifeArc filed Critical Universitaetsmedizin Goettingen Georg August Universitaet
Publication of CA3114669A1 publication Critical patent/CA3114669A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3114669A 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody Pending CA3114669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816210.7 2018-10-04
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (1)

Publication Number Publication Date
CA3114669A1 true CA3114669A1 (en) 2020-04-09

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3114669A Pending CA3114669A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Country Status (13)

Country Link
US (1) US12297261B2 (https=)
EP (1) EP3861023A1 (https=)
JP (1) JP7610515B2 (https=)
KR (1) KR102862077B1 (https=)
CN (1) CN113056480B (https=)
AU (1) AU2019354714A1 (https=)
BR (1) BR112021006153A2 (https=)
CA (1) CA3114669A1 (https=)
EA (1) EA202190954A1 (https=)
IL (1) IL281979B2 (https=)
MX (1) MX2021003867A (https=)
SG (1) SG11202102765RA (https=)
WO (1) WO2020070225A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP4118111A1 (en) * 2020-03-10 2023-01-18 LifeArc Cyclic peptides

Also Published As

Publication number Publication date
JP7610515B2 (ja) 2025-01-08
BR112021006153A2 (pt) 2021-06-29
MX2021003867A (es) 2021-09-08
JP2022513331A (ja) 2022-02-07
EA202190954A1 (ru) 2021-06-29
US20210347867A1 (en) 2021-11-11
EP3861023A1 (en) 2021-08-11
CN113056480A (zh) 2021-06-29
AU2019354714A1 (en) 2021-04-29
SG11202102765RA (en) 2021-04-29
KR102862077B1 (ko) 2025-09-18
IL281979B2 (en) 2025-09-01
KR20210080400A (ko) 2021-06-30
US12297261B2 (en) 2025-05-13
IL281979B1 (en) 2025-05-01
IL281979A (en) 2021-05-31
CN113056480B (zh) 2025-06-13
US20230203140A9 (en) 2023-06-29
WO2020070225A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11440954B2 (en) Optimized anti-TL1A antibodies
US12297261B2 (en) Humanised anti-n-truncated amyloid β monoclonal antibody
JP7045724B2 (ja) 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
TW202019465A (zh) 抗ｔｉｇｉｔ抗體及其用途
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
JP2020124203A (ja) 血液脳関門輸送分子およびそれらの使用
TW200944234A (en) Humanized anti-Factor D antibodies and uses thereof
TWI833742B (zh) Ｃ３結合劑及其使用方法
AU2008334637A1 (en) Antigen binding proteins
KR20120075457A (ko) 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도
CN106459210A (zh) 用于治疗糖尿病黄斑性水肿的组合物和方法
TW202305010A (zh) 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
CN117015553A (zh) 包含白细胞介素-18结合蛋白和抗血清白蛋白的抗原结合片段的重组融合蛋白及其组合物和用途
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
AU2019394099B2 (en) Humanised anti-IL17BR antibody
RU2830101C1 (ru) Антитело к angptl3 и его применение
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
WO2026012421A1 (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
US20230227541A1 (en) Anti-myocilin olf antibodies and methods of use thereof
HK40049308A (en) Anti-lag-3 agonistic antibodies
HK1256116B (en) Anti-lag-3 antibodies
HK1256116A1 (en) Anti-lag-3 antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220823

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250306

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250402

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250714

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251107

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260226